[Recollection of the first heparin era].

E. Jorpes

Chemotherapia

Abstract:

What problem does this paper attempt to address?

The heparin recall of 2008

KD Hedlund,DP Coyne,DM Sanford,J Huddelson

DOI: https://doi.org/10.1177/0267659112462274

2012-10-05

Perfusion

Abstract:Heparin is one of the oldest drugs still in widespread clinical use. Its discovery in 1916 predates the establishment of the Food and Drug Administration. Since 1935, over 15,000 research papers have been published on the effects of heparin. Because the exact chemical formula of heparin is unknown, synthetic manufacturing has proven difficult. In 2008, a worldwide recall of heparin occurred. Scientists determined that a contaminant known as oversulfated chondroitin sulfate was responsible for the numerous deaths and adverse events. This contaminant was first traced to a chemical plant in Changzou, China. This article will review the discovery of heparin and the adulteration process that jeopardized the world’s heparin supply.
Heparin and Related Polysaccharides

DOI: https://doi.org/10.1007/978-1-4899-2444-5

1992-01-01

Advances in experimental medicine and biology

Abstract:This volume is a record of a meeting entitled "Heparin and Related Polysaccharides" that was held at the Biomedical Center, Uppsala, Sweden between 1-6 September 1991. The meeting was hosted by U. Lindahl, L. Kjellen and I. Bjork, who were helped in their preparations by a scientific advisory panel that included U. Abildgaard, B. Casu, E. Holmer and D. Lane. Altogether, 230 participants from 18 countries attended the meeting, and most were present to be included in a photograph, which is to be found at the end of this volume. The selection of presentations for inclusion in the Symposia of the meeting was made on the basis of the known high quality of the work of the individuals or groups involved. This, we believe, is reflected in the contents of the enclosed articles, which collectively give a comprehensive overview of the present state of knowledge of heparin and related compounds. Some of the areas covered are evolving or controversial and the views expressed in each article should be regarded as those of the author(s). The authors have taken various amounts of care to define all their abbreviations and some familiarity with the different forms of nomenclature used in the fields of polysaccharide chemistry and of the coagulation proteinases and their inhibitors will assist the reader.

medicine, research & experimental,biology
Correction: Evaluation of a Novel Thermosensitive Heparin-Poloxamer Hydrogel for Improving Vascular Anastomosis Quality and Safety in a Rabbit Model.

Ying-Zheng Zhao,Hai-Feng Lv,Cui-Tao Lu,Li-Juan Chen,Min Lin,Ming Zhang,Xi Jiang,Xiao-Tong Shen,Rong-Rong Jin,Jun Cai,Xin-Qiao Tian,Ho Lun Wong

DOI: https://doi.org/10.1371/journal.pone.0073178

IF: 3.7

2013-01-01

PLoS ONE

Abstract:Despite progress in the design of advanced surgical techniques, stenosis recurs in a large percentage of vascular anastomosis. In this study, a novel heparin-poloxamer (HP) hydrogel was designed and its effects for improving the quality and safety of vascular anastomosis were studied. HP copolymer was synthesized and its structure was confirmed by Fourier transform infrared spectroscopy (FTIR) and nuclear magnetic resonance spectroscopy ((1)H-NMR). Hydrogels containing HP were prepared and their important characteristics related to the application in vascular anastomosis including gelation temperature, rheological behaviour and micromorphology were measured. Vascular anastomosis were performed on the right common carotid arteries of rabbits, and the in vivo efficiency and safety of HP hydrogel to achieve vascular anastomosis was verified and compared with Poloxamer 407 hydrogel and the conventional hand-sewn method using Doppler ultrasound, CT angiograms, scanning electron microscopy (SEM) and histological technique. Our results showed that HP copolymer displayed special gel-sol-gel phase transition behavior with increasing temperature from 5 to 60 °C. HP hydrogel prepared from 18 wt% HP solution had a porous sponge-like structure, with gelation temperature at approximately 38 °C and maximum elastic modulus at 10,000 Pa. In animal studies, imaging and histological examination of rabbit common jugular artery confirmed that HP hydrogel group had similar equivalent patency, flow and burst strength as Poloxamer 407 group. Moreover, HP hydrogel was superior to poloxamer 407 hydrogel and hand-sewn method for restoring the functions and epithelial structure of the broken vessel junctions after operation. By combining the advantages of heparin and poloxamer 407, HP hydrogel holds high promise for improving vascular anastomosis quality and safety.
Heparin Conjugate Pretreatment of Kidneys From Deceased Donors Before Transplantation: Results From the First-in-human Randomized Phase I Trial

Amir Sedigh,Torbjörn Lundgren,Per Lindnér,Johan Nordström,Peetra Magnusson,Janniz Jönsson,Fredrik Carlsson,Rutger Ploeg,Tomas Lorant

DOI: https://doi.org/10.1097/TXD.0000000000001403

2022-12-22

Abstract:Pretreating porcine kidneys with Corline Heparin Conjugate (CHC) during hypothermic machine perfusion (HMP) has been shown to reduce preservation injury and improve early kidney function. In this first-in-human phase I study, the safety and tolerability of transplanting CHC-pretreated kidneys were evaluated. Methods: CHC or placebo was added to the preservation solution during HMP of donated kidneys from deceased donors for at least 3 h before transplantation into adult patients. The primary safety endpoint was the number and severity of adverse events (AEs) and serious AEs (SAEs) during the first 30 d after transplantation. Results: In the first 30 d, 66 AEs were reported in 8 patients who received CHC-pretreated kidneys with 39 AEs in 8 patients who received placebo-pretreated kidneys (P = 0.1 in post hoc analysis). The most common AEs were hypertension (CHC, n = 5; placebo, n = 2) and anemia (CHC, n = 5; placebo, n = 2). Most AEs were assessed as mild (58%) or moderate (39%) and not related to treatment (95%). There were 2 SAEs reported in each group. One SAE, considered possibly related to CHC treatment, was a case of severe postprocedural hemorrhage that required reoperation. No patients needed dialysis. There were no observed rejections and no patient deaths. Conclusions: Pretreatment of kidneys with CHC before transplantation was considered safe and tolerable. Efficacy studies are now planned to investigate if CHC can reduce early ischemia-reperfusion injury in humans.
[Transmission of medical information about patients who died of cancer to their heirs. Experience over 4 years and 57 cases].

B. Hoerni,J. Reiffers

DOI: https://doi.org/10.1016/J.LPM.2007.01.036

2007-03-26

Presse Medicale

Abstract:
Pharmacology of Heparin and Related Drugs

Barbara Mulloy,John Hogwood,Elaine Gray,Rebecca Lever,Clive P. Page

DOI: https://doi.org/10.1124/pr.115.011247

2015-12-15

Pharmacological Reviews

Abstract:Heparin has been recognized as a valuable anticoagulant and antithrombotic for several decades and is still widely used in clinical practice for a variety of indications. The anticoagulant activity of heparin is mainly attributable to the action of a specific pentasaccharide sequence that acts in concert with antithrombin, a plasma coagulation factor inhibitor. This observation has led to the development of synthetic heparin mimetics for clinical use. However, it is increasingly recognized that heparin has many other pharmacological properties, including but not limited to antiviral, anti-inflammatory, and antimetastatic actions. Many of these activities are independent of its anticoagulant activity, although the mechanisms of these other activities are currently less well defined. Nonetheless, heparin is being exploited for clinical uses beyond anticoagulation and developed for a wide range of clinical disorders. This article provides a "state of the art" review of our current understanding of the pharmacology of heparin and related drugs and an overview of the status of development of such drugs.

pharmacology & pharmacy
Pleiotropic Effects of Heparin and its Monitoring in the Clinical Practice

Deepa J. Arachchillage,Steve Kitchen

DOI: https://doi.org/10.1055/s-0044-1786990

2024-05-30

Seminars in Thrombosis and Hemostasis

Abstract:Unfractionated heparin (UFH) was uncovered in 1916, has been used as an anticoagulant since 1935, and has been listed in the World Health Organization's Model List of Essential Medicines. Despite the availability of many other anticoagulants, the use of heparin (either low molecular weight heparin [LMWH] or UFH) is still substantial. Heparin has pleotropic effects including anticoagulant and several nonanticoagulant properties such as antiproliferative, anti-inflammatory activity, and anticomplement effects. Although UFH has been widely replaced by LMWH, UFH is still the preferred anticoagulant of choice for patients undergoing cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, and patients with high-risk mechanical cardiac valves requiring temporary bridging with a parenteral anticoagulant. UFH is a highly negatively charged molecule and binds many positively charged molecules, hence has unpredictable pharmacokinetics, and variable anticoagulant effect on an individual patient basis. Therefore, anticoagulant effects of UFH may not be proportional to the dose of UFH given to any individual patient. In this review, we discuss the anticoagulant and nonanticoagulant activities of UFH, differences between UFH and LMWH, when to use UFH, different methods of monitoring the anticoagulant effects of UFH (including activated partial thromboplastin time, heparin anti-Xa activity level, and activated clotting time), while discussing pros and cons related to each method and comparison of clinical outcomes in patients treated with UFH monitored with different methods based on available evidence. D.J.A. designed the manuscript. Both D.J.A. and S.K. wrote, reviewed, and approved the final manuscript. Article published online: 29 May 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

peripheral vascular disease,hematology
From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods

Jan-Ytzen Van der Meer,Edwin Kellenbach,Leendert Van den Bos,,

DOI: https://doi.org/10.3390/molecules22061025

IF: 4.6

2017-06-21

Molecules

Abstract:The purification of heparin from offal is an old industrial process for which commercial recipes date back to 1922. Although chemical, chemoenzymatic, and biotechnological alternatives for this production method have been published in the academic literature, animal-tissue is still the sole source for commercial heparin production in industry. Heparin purification methods are closely guarded industrial secrets which are not available to the general (scientific) public. However by reviewing the academic and patent literature, we aim to provide a comprehensive overview of the general methods used in industry for the extraction of heparin from animal tissue.

chemistry, multidisciplinary,biochemistry & molecular biology
Heparin: Effects upon the Glycocalyx and Endothelial Cells.

B. Spiess

DOI: https://doi.org/10.1051/ject/201749192

2017-09-01

Abstract:Unfractionated heparin (UFH) is the most widely used injectable medication in the United States. UFH is a poly-dispersed, relatively impure combination of many polysaccharides known as a glycosaminoglycan. It is used as the primary anticoagulant for heart surgery as well as for active treatment of deep venous thrombosis, vascular thrombosis, stroke, and many other potentially catastrophic clotting syndromes. Many perfusionists and cardiac team members know little of the biology of UFH other than its use for cardiopulmonary bypass. UFH is very similar to heparin sulfate, found on the surface of endothelial cells. Heparan sulfate protects endothelial surfaces from inflammatory attack and serves as a mechano-transducer for vascular shear. UFH and all glycosaminoglycans have far reaching pleotropic actions. This review elaborates on some of fascinating unique biology of these polysaccharides. Perhaps a number of the complex complications attributed to CPB are either caused by, or set up to occur by the complicated biology of UFH?

Medicine,Biology
Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy

Razia Sultana,Masamichi Kamihira

DOI: https://doi.org/10.3390/ph17101362

IF: 4.6

2024-10-13

Pharmaceuticals

Abstract:Heparin, a naturally occurring polysaccharide, has fascinated researchers and clinicians for nearly a century due to its versatile biological properties and has been used for various therapeutic purposes. Discovered in the early 20th century, heparin has been a key therapeutic anticoagulant ever since, and its use is now implemented as a life-saving pharmacological intervention in the management of thrombotic disorders and beyond. In addition to its known anticoagulant properties, heparin has been found to exhibit anti-inflammatory, antiviral, and anti-tumorigenic activities, which may lead to its widespread use in the future as an essential drug against infectious diseases such as COVID-19 and in various medical treatments. Furthermore, recent advancements in nanotechnology, including nano-drug delivery systems and nanomaterials, have significantly enhanced the intrinsic biofunctionalities of heparin. These breakthroughs have paved the way for innovative applications in medicine and therapy, expanding the potential of heparin research. Therefore, this review aims to provide a creation profile of heparin, space for its utilities in therapeutic complications, and future characteristics such as bioengineering and nanotechnology. It also discusses the challenges and opportunities in realizing the full potential of heparin to improve patient outcomes and elevate therapeutic interventions.

pharmacology & pharmacy,chemistry, medicinal
Drug Determination in Therapeutic and Forensic Contexts

E. Reid,I. Wilson

DOI: https://doi.org/10.1007/978-1-4613-2397-6

2012-10-20

Abstract:
A comparative study on the use of a HA/collagen/chondroitin sulphate biomaterial (Biostite) and a bovine-derived HA xenograft (Bio-Oss) in the treatment of deep intra-osseous defects.

A. Scabbia,L. Trombelli

DOI: https://doi.org/10.1111/J.1600-051X.2004.00483.X

IF: 7.478

2004-05-01

Journal Of Clinical Periodontology

Abstract:OBJECTIVES This parallel-group, randomized, clinical trial was designed to evaluate the clinical outcome of deep intra-osseous defects following reconstructive surgery with the use of a synthetic hydroxyapatite/equine Type I collagen/chondroitin sulphate biomaterial (Biostite), as compared to a bovine-derived hydroxyapatite xenograft (Bio-Oss). MATERIAL AND METHODS Twenty-four systemically healthy subjects with moderate to advanced periodontitis, 11 females and 13 males, aged 30-64 years, seven smokers, were selected. Patients presented with one interproximal deep intra-osseous defect (intra-osseous component >or=4 mm) as clinically and radiographically evaluated. Immediately before surgery and 12 months after surgery, pocket probing depth (PPD), clinical attachment level (CAL) and radiographic depth of the defect (DEPTH) were evaluated. RESULTS Thirteen defects were treated with Biostite (test) and 11 defects with Bio-Oss (control). In the test group, PPD amounted to 7.8+/-1.3 mm before surgery, and decreased significantly to 3.6+/-1.6 mm 12 months following surgery, while in the control group PPD significantly decreased from 7.5+/-2.0 mm pre-surgery to 3.1+/-1.0 mm post-surgery. At 1 year, CAL gain and DEPTH gain were 2.9+/-1.9 and 2.5+/-1.4 mm, respectively, in the test group, and 4.0+/-2.4 mm and 3.1+/-1.8 mm, respectively, in the control group. No statistically significant differences for PPD reduction, CAL gain and DEPTH gain were detected between the groups. CONCLUSIONS The results of the present study indicate that both Biostite and Bio-Oss grafting biomaterials have determined a clinically and statistically significant improvement in terms of CAL gain, PPD reduction and radiographic DEPTH gain when used for the treatment of deep intra-osseous defects.
The Most Highly Cited Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 50 Years in the Making

Emmanuel J. Favaloro

DOI: https://doi.org/10.1055/s-0043-1775756

2023-09-29

Seminars in Thrombosis and Hemostasis

Abstract:Welcome to another editorial relating to our celebration of 50 years of publishing for Seminars in Thrombosis & Hemostasis (STH). As noted several times previously, 2024 marks the 50th birthday of STH, which first published in 1974.[1] A half-century of publishing is a landmark worthy of celebration. We started the celebrations in 2022, when we published our first 50th year celebratory issue.[2] A second celebratory issue was published in 2023,[3] and a third compilation was published as the first issue of 2024.[4] All issues were rich in content of a historical nature related to the fields of thrombosis and hemostasis. We plan to prepare a 4th and final 50th year celebratory compilation later in this year. In the interim, we plan to publish a separate tribute to the rich history of STH in each issue of STH publishing in 2024. For the first issue of 2024, we republished the first paper ever published in STH, on the molecular structure of fibrinogen,[5] together with an accompanying commentary from Neerman-Arbez and Casini.[6] In the next few issues of STH, we will republish the most highly cited publications from STH of all time, as also accompanied by commentaries from experts in these specific featured fields. This editorial is accompanying the second issue of STH for 2024 and provides two tables that outline the most highly cited papers from STH. [Table 1] identifies the 100 manuscripts that have been most highly cited over the entire publication history of STH, starting from the first paper published in 1974.[5] These papers have a citation count of 119 or more. Naturally, in such a listing, papers published earlier in the STH publication timeline have considerable advantage in terms of overall citations compared to more recent publications. However, this is still an important analysis for our journal. I would like to make a few comments on this listing. First, three of the papers on the top 100 list were authored by the founding editor in chief of STH, Eberhard F. Mammen. This included two papers on the platelet function analyzer (PFA)-100.[7] [8] It is likely that these papers helped the manufacturer obtain regulatory approvals for clinical use of the PFA-100 in hemostasis laboratories. Another paper on the PFA-100, the first full report to describe the instrument,[9] is understandably also a highly cited paper, listing third on the table. Another paper on the PFA-100 in [Table 1] is my own contribution,[10] written as a tribute to Eberhard Mammen, following his passing in 2008.[11] [12] STH has published several more recent publications mentioning the PFA-100, including its recent remodeling as the PFA-200.[13] [14] [15] Rank Citation Publication year 1 Baskurt OK, Meiselman HJ. Blood rheology and hemodynamics. Semin Thromb Hemost. 2003 Oct;29(5):435–450. 2003 2 Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost. 1990 Jan;16(1):1–20. 1990 3 Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer–PFA-100. Semin Thromb Hemost. 1995;21 Suppl 2:106–112. 1995 4[b] Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost. 1998;24(2):195–202. 1998 5 Linhardt RJ, Gunay NS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost. 1999;25 Suppl 3:5–16. 1999 6 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost. 2005;31(4):381–392. 2005 7 Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Semin Thromb Hemost. 2004 Oct;30(5):579–589. 2004 8 Hellgren M. Hemostasis during normal pregnancy and puerperium. Semin Thromb Hemost. 2003 Apr;29(2):125–130. 2003 9 Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost. 1991;17 Suppl 3:304–312. 1991 10 Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the Tumor Vasculature. Semin Thromb Hemost. 2010 Apr;36(3):321–331. 2010 11 Finkelstein JD. Pathways and regulation of homocysteine metabolism in mammals. Semin Thromb Hemost. 2000;26(3):219–225. 2000 12 Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost. 2005 Apr;31(2):174–183. 2005 13[b] Mammen EF, Koets MH, Washington BC, Wolk LW, Brown JM, Burdick M, Selik NR, Wilson RF. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost. 1985 Jul;11(3):281–292. 1985 14 Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost. 1997;23(4):349–356. 1997 15 Tschoep -Abstract Truncated-

peripheral vascular disease,hematology
Inhaled heparin: Past, present, and future

Zhewei Liu,Yuqing Ye,Ying Ma,Binjie Hu,Jesse Zhu

DOI: https://doi.org/10.1016/j.drudis.2024.104065

IF: 8.369

2024-06-22

Drug Discovery Today

Abstract:While heparin has traditionally served as a key anticoagulant in clinical practice for nearly a century, recent years have witnessed a growing interest in its role as a potent antiinflammatory and antiviral agent, as well as an anticancer agent. To address challenges with injection-based delivery, exploring patient-friendly routes such as oral and pulmonary delivery is crucial. This review specifically highlights the multiple therapeutic benefits of inhaled heparin. In summary, this review...

pharmacology & pharmacy
External Trigger Free Charge Switchable Cationic Ligands in the Design of Safe and Effective Universal Heparin Antidote

Chanel C. La,Stephanie A. Smith,Manu Thomas Kalathottukaren,Charles A. Haynes,James H. Morrissey,Jayachandran N. Kizhakkedathu

DOI: https://doi.org/10.1002/adhm.202400108

IF: 10

2024-03-29

Advanced Healthcare Materials

Abstract:Thrombosis, the formation of blood clots within a blood vessel, can lead to severe complications including pulmonary embolism, cardiac arrest, and stroke. The most widely administered class of anticoagulants is heparin‐based anticoagulants such as unfractionated heparin (UFH), low‐molecular weight heparins (LMWHs), and fondaparinux. Protamine is the only FDA approved heparin antidote. Protamine has limited efficacy neutralizing LMWHs and no reversal activity against fondaparinux. The use of protamine can lead to complications, including excessive bleeding, hypotension and hypersensitivity, and has narrow therapeutic window. In this work, we present a new concept in the design of a universal heparin antidote: switchable protonation of cationic ligands. A library of macromolecular polyanion inhibitors (MPIs) was synthesized and screened to identify molecules that can neutralize all heparins with high selectivity and reduced toxicity. MPIs were developed by assembling cationic binding groups possessing switchable protonation states onto a polymer scaffold. By strategically selecting the identity and modulating the density of cationic binding groups on the polymer scaffold, a superior universal heparin reversal agent was developed with improved heparin‐binding activity and increased hemocompatibility profiles leading to minimal effect on hemostasis. The activity of this heparin antidote was demonstrated using in vitro and in vivo studies. This article is protected by copyright. All rights reserved

nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
Shrunken Dissimilarity Measure for Genome-wide SNP Data Classification ∗

Haiyong Liao,Yang Liu,M. Ng

Abstract:Recent development of high-resolution single-nucleotide polymorphism (SNP) arrays allows detailed assessment of genome-wide human genome variations. However, SNP data typi- cally has a large number of SNPs (e.g., 400 thousand SNPs in genome-wide Parkinson disease SNP data) and a few hundred of samples. Conventional classification methods may not be effective when applied to such genome-wide SNP data. In this paper, we propose to develop and use shrunken dis- similarity measure to analyze and select relevant SNPs for classification problems. Examples for HapMap data and Parkinson data are given to demonstrate the effectiveness of the proposed method and illustrate it has the potential to become a useful analysis tool for SNP data sets. In particular, we find some SNPs in chromosome 2 that they contain in some genes which is relevant to Parkinson disease.
Not Just Anticoagulation—New and Old Applications of Heparin

Lixuan Zang,Haomiao Zhu,Kun Wang,Yonghui Liu,Fan Yu,Wei Zhao

DOI: https://doi.org/10.3390/molecules27206968

IF: 4.6

2022-10-18

Molecules

Abstract:In recent decades, heparin, as the most important anticoagulant drug, has been widely used in clinical settings to prevent and treat thrombosis in a variety of diseases. However, with in-depth research, the therapeutic potential of heparin is being explored beyond anticoagulation. To date, heparin and its derivatives have been tested in the protection against and repair of inflammatory, antitumor, and cardiovascular diseases. It has also been explored as an antiangiogenic, preventive, and antiviral agent for atherosclerosis. This review focused on the new and old applications of heparin and discussed the potential mechanisms explaining the biological diversity of heparin.

chemistry, multidisciplinary,biochemistry & molecular biology
Development of a Selective Enzyme-Linked Immunosorbent Assay for l-Naphthol-the Major Metabolite of Carbaryl ( l-Naphthyl N-Met h ylcar bamate ) Pet

ra M. Kriimer,M. Marco,B. Hammock

Abstract:published in Advance ACS Abstracts, February 15, 1994.
Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism

Maureen A. Smythe,Jennifer Priziola,Paul P. Dobesh,Diane Wirth,Adam Cuker,Ann K. Wittkowsky

DOI: https://doi.org/10.1007/s11239-015-1315-2

2016-01-01

Journal of Thrombosis and Thrombolysis

Abstract:Venous thromboembolism (VTE) is a serious and often fatal medical condition with an increasing incidence. Despite the changing landscape of VTE treatment with the introduction of the new direct oral anticoagulants many uncertainties remain regarding the optimal use of traditional parenteral agents. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. This specific chapter addresses the practical management of heparins including low molecular weight heparins and fondaparinux. For each anticoagulant a list of the most common practice related questions were created. Each question was addressed using a brief focused literature review followed by a multidisciplinary consensus guidance recommendation. Issues addressed included initial anticoagulant dosing recommendations, recommended baseline laboratory monitoring, managing dose adjustments, evidence to support a relationship between laboratory tests and meaningful clinical outcomes, special patient populations including extremes of weight and renal impairment, duration of necessary parenteral therapy during the transition to oral therapy, candidates for outpatient treatment where appropriate and management of over-anticoagulation and adverse effects including bleeding and heparin induced thrombocytopenia. This article concludes with a concise table of clinical management questions and guidance recommendations to provide a quick reference for the practical management of heparin, low molecular weight heparin and fondaparinux.

cardiac & cardiovascular systems,peripheral vascular disease,hematology
Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin

Sultan N Baytas,Sony S Varghese,Weihua Jin,Yanlei Yu,Peng He,Marc Douaisi,Fuming Zhang,Paul Brodfuehrer,Ke Xia,Jonathan S Dordick,Robert J Linhardt,Sultan N. Baytas,Sony S. Varghese,Jonathan S. Dordick,Robert J. Linhardt

DOI: https://doi.org/10.1021/acs.jmedchem.0c02019

IF: 8.039

2021-02-15

Journal of Medicinal Chemistry

Abstract:Bovine intestinal heparins are structurally distinct from porcine intestinal heparins and exhibit lower specific anticoagulant activity (units/mg). The reduced content of N-sulfo, 3-O-sulfo glucosamine, the central and critical residue in heparin's antithrombin III binding site, is responsible for bovine intestinal heparin's reduced activity. Previous studies demonstrate that treatment of bovine intestinal heparin with 3-O-sulfotransferase in the presence of 3′-phosphoadenosine-5′-phosphosulfate afforded remodeled bovine heparin with an enhanced activity reaching the United States Pharmacopeia's requirements. Starting from this remodeled bovine intestinal heparin, we report the preparation of a bovine intestinal low molecular weight heparin having the same structural properties and anti-factor IIa and anti-factor Xa activities of Enoxaparin. Moreover, this bovine intestinal heparin-derived "Enoxaparin" showed comparable platelet factor-4 binding affinity, suggesting that it should exhibit similarly low levels of heparin induced thrombocytopeneia, HIT.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02019?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02019</a>.Additional figures stacked 1H NMR spectrum of Enoxaparin and remodeled bovine LMWH batch 11, and disaccharide and tetrasaccharide compositions and 1,6-anhydro analysis of prepared bovine intestinal LMWH (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02019/suppl_file/jm0c02019_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

chemistry, medicinal

[Recollection of the first heparin era].

The heparin recall of 2008

Heparin and Related Polysaccharides

Correction: Evaluation of a Novel Thermosensitive Heparin-Poloxamer Hydrogel for Improving Vascular Anastomosis Quality and Safety in a Rabbit Model.

Heparin Conjugate Pretreatment of Kidneys From Deceased Donors Before Transplantation: Results From the First-in-human Randomized Phase I Trial

[Transmission of medical information about patients who died of cancer to their heirs. Experience over 4 years and 57 cases].

Pharmacology of Heparin and Related Drugs

Pleiotropic Effects of Heparin and its Monitoring in the Clinical Practice

From Farm to Pharma: An Overview of Industrial Heparin Manufacturing Methods

Heparin: Effects upon the Glycocalyx and Endothelial Cells.

Multifaceted Heparin: Diverse Applications beyond Anticoagulant Therapy

Drug Determination in Therapeutic and Forensic Contexts

A comparative study on the use of a HA/collagen/chondroitin sulphate biomaterial (Biostite) and a bovine-derived HA xenograft (Bio-Oss) in the treatment of deep intra-osseous defects.

The Most Highly Cited Publications from Seminars in Thrombosis and Hemostasis: A Data Analysis 50 Years in the Making

Inhaled heparin: Past, present, and future

External Trigger Free Charge Switchable Cationic Ligands in the Design of Safe and Effective Universal Heparin Antidote

Shrunken Dissimilarity Measure for Genome-wide SNP Data Classification ∗

Not Just Anticoagulation—New and Old Applications of Heparin

Development of a Selective Enzyme-Linked Immunosorbent Assay for l-Naphthol-the Major Metabolite of Carbaryl ( l-Naphthyl N-Met h ylcar bamate ) Pet

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism

Preparation of Low Molecular Weight Heparin from a Remodeled Bovine Intestinal Heparin